Literature DB >> 27069956

PD-1, PD-L1 and PD-L2 expression in mouse prostate cancer.

Shijie Yang1, Qiuyang Zhang2, Sen Liu2, Alun R Wang3, Zongbing You4.   

Abstract

Programmed cell death protein 1 (PD-1) and its ligands PD-L1 and PD-L2 play critical roles in maintaining an immunosuppressive tumor microenvironment. The purpose of the present study was to assess expression of PD-1, PD-L1, and PD-L2 in mouse prostate tumors. A total of 33 mouse prostate tumors derived from Pten-null mice were examined using immunohistochemical staining for PD-1, PD-L1, and PD-L2. The animals were either with interleukin-17 receptor c (Il-17rc) wild-type or knockout genotype, or fed with regular diet or high-fat diet to 30 weeks of age. We found that Il-17rc wild-type mouse prostate tumors had significantly higher levels of PD-1, PD-L1, and PD-L2 than Il-17rc knockout mouse prostate tumors. High-fat diet-induced obese mice had significantly higher levels of PD-1, PD-L1, and PD-L2 in their prostate tumors than lean mice fed with regular diet. Increased expression of PD-1, PD-L1, and PD-L2 was associated with increased number of invasive prostate tumors formed in the Il-17rc wild-type and obese mice compared to the Il-17rc knockout and lean mice, respectively. Our findings suggest that expression of PD-1, PD-L1, and PD-L2 may enhance development of mouse prostate cancer through creating an immunosuppressive tumor microenvironment.

Entities:  

Keywords:  IL-17; PD-1; PD-L1; PD-L2; Prostate cancer; obesity

Year:  2016        PMID: 27069956      PMCID: PMC4749401     

Source DB:  PubMed          Journal:  Am J Clin Exp Urol        ISSN: 2330-1910


  33 in total

Review 1.  Prostate cancer immunotherapy: beyond immunity to curability.

Authors:  Jonathan W Simons
Journal:  Cancer Immunol Res       Date:  2014-11       Impact factor: 11.151

2.  Tumor microenvironment and metabolism in prostate cancer.

Authors:  Paola Chiarugi; Paolo Paoli; Paolo Cirri
Journal:  Semin Oncol       Date:  2014-03-05       Impact factor: 4.929

3.  Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients.

Authors:  Roy S Herbst; Jean-Charles Soria; Marcin Kowanetz; Gregg D Fine; Omid Hamid; Michael S Gordon; Jeffery A Sosman; David F McDermott; John D Powderly; Scott N Gettinger; Holbrook E K Kohrt; Leora Horn; Donald P Lawrence; Sandra Rost; Maya Leabman; Yuanyuan Xiao; Ahmad Mokatrin; Hartmut Koeppen; Priti S Hegde; Ira Mellman; Daniel S Chen; F Stephen Hodi
Journal:  Nature       Date:  2014-11-27       Impact factor: 49.962

4.  Safety, activity, and immune correlates of anti-PD-1 antibody in cancer.

Authors:  Suzanne L Topalian; F Stephen Hodi; Julie R Brahmer; Scott N Gettinger; David C Smith; David F McDermott; John D Powderly; Richard D Carvajal; Jeffrey A Sosman; Michael B Atkins; Philip D Leming; David R Spigel; Scott J Antonia; Leora Horn; Charles G Drake; Drew M Pardoll; Lieping Chen; William H Sharfman; Robert A Anders; Janis M Taube; Tracee L McMiller; Haiying Xu; Alan J Korman; Maria Jure-Kunkel; Shruti Agrawal; Daniel McDonald; Georgia D Kollia; Ashok Gupta; Jon M Wigginton; Mario Sznol
Journal:  N Engl J Med       Date:  2012-06-02       Impact factor: 91.245

5.  Nivolumab plus ipilimumab in advanced melanoma.

Authors:  Jedd D Wolchok; Harriet Kluger; Margaret K Callahan; Michael A Postow; Naiyer A Rizvi; Alexander M Lesokhin; Neil H Segal; Charlotte E Ariyan; Ruth-Ann Gordon; Kathleen Reed; Matthew M Burke; Anne Caldwell; Stephanie A Kronenberg; Blessing U Agunwamba; Xiaoling Zhang; Israel Lowy; Hector David Inzunza; William Feely; Christine E Horak; Quan Hong; Alan J Korman; Jon M Wigginton; Ashok Gupta; Mario Sznol
Journal:  N Engl J Med       Date:  2013-06-02       Impact factor: 91.245

6.  Prostate-specific deletion of the murine Pten tumor suppressor gene leads to metastatic prostate cancer.

Authors:  Shunyou Wang; Jing Gao; Qunying Lei; Nora Rozengurt; Colin Pritchard; Jing Jiao; George V Thomas; Gang Li; Pradip Roy-Burman; Peter S Nelson; Xin Liu; Hong Wu
Journal:  Cancer Cell       Date:  2003-09       Impact factor: 31.743

7.  The tumor microenvironment in prostate cancer: elucidating molecular pathways for therapy development.

Authors:  Paul G Corn
Journal:  Cancer Manag Res       Date:  2012-07-25       Impact factor: 3.989

8.  PD-L1 is highly expressed in Enzalutamide resistant prostate cancer.

Authors:  Jennifer L Bishop; Alexander Sio; Arkhjamil Angeles; Morgan E Roberts; Arun A Azad; Kim N Chi; Amina Zoubeidi
Journal:  Oncotarget       Date:  2015-01-01

9.  Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death.

Authors:  Y Ishida; Y Agata; K Shibahara; T Honjo
Journal:  EMBO J       Date:  1992-11       Impact factor: 11.598

10.  Paucity of PD-L1 expression in prostate cancer: innate and adaptive immune resistance.

Authors:  A M Martin; T R Nirschl; C J Nirschl; B J Francica; C M Kochel; A van Bokhoven; A K Meeker; M S Lucia; R A Anders; A M DeMarzo; C G Drake
Journal:  Prostate Cancer Prostatic Dis       Date:  2015-08-11       Impact factor: 5.554

View more
  17 in total

Review 1.  Microbiome, bile acids, and obesity: How microbially modified metabolites shape anti-tumor immunity.

Authors:  Laura M Sipe; Mehdi Chaib; Ajeeth K Pingili; Joseph F Pierre; Liza Makowski
Journal:  Immunol Rev       Date:  2020-05       Impact factor: 12.988

2.  Posttranscriptional Control of PD-L1 Expression by 17β-Estradiol via PI3K/Akt Signaling Pathway in ERα-Positive Cancer Cell Lines.

Authors:  Lingyun Yang; Feng Huang; Jiandong Mei; Xun Wang; Qiuyang Zhang; Hongjing Wang; Mingrong Xi; Zongbing You
Journal:  Int J Gynecol Cancer       Date:  2017-02       Impact factor: 3.437

Review 3.  Contribution of Adipose Tissue to Development of Cancer.

Authors:  Alyssa J Cozzo; Ashley M Fuller; Liza Makowski
Journal:  Compr Physiol       Date:  2017-12-12       Impact factor: 9.090

Review 4.  PD-1/PD-L1 pathway: current researches in cancer.

Authors:  Yanyan Han; Dandan Liu; Lianhong Li
Journal:  Am J Cancer Res       Date:  2020-03-01       Impact factor: 6.166

Review 5.  The Controversial Role of PD-1 and Its Ligands in Gynecological Malignancies.

Authors:  Oliviero Marinelli; Daniela Annibali; Cristina Aguzzi; Sandra Tuyaerts; Frédéric Amant; Maria Beatrice Morelli; Giorgio Santoni; Consuelo Amantini; Federica Maggi; Massimo Nabissi
Journal:  Front Oncol       Date:  2019-10-15       Impact factor: 6.244

6.  What Do We Have to Know about PD-L1 Expression in Prostate Cancer? A Systematic Literature Review. Part 4: Experimental Treatments in Pre-Clinical Studies (Cell Lines and Mouse Models).

Authors:  Andrea Palicelli; Stefania Croci; Alessandra Bisagni; Eleonora Zanetti; Dario De Biase; Beatrice Melli; Francesca Sanguedolce; Moira Ragazzi; Magda Zanelli; Alcides Chaux; Sofia Cañete-Portillo; Maria Paola Bonasoni; Alessandra Soriano; Stefano Ascani; Maurizio Zizzo; Carolina Castro Ruiz; Antonio De Leo; Guido Giordano; Matteo Landriscina; Giuseppe Carrieri; Luigi Cormio; Daniel M Berney; Jatin Gandhi; Giacomo Santandrea; Martina Bonacini
Journal:  Int J Mol Sci       Date:  2021-11-14       Impact factor: 5.923

Review 7.  Immunotherapy as a Promising Treatment for Prostate Cancer: A Systematic Review.

Authors:  Marlena Janiczek; Łukasz Szylberg; Anna Kasperska; Adam Kowalewski; Martyna Parol; Paulina Antosik; Barbara Radecka; Andrzej Marszałek
Journal:  J Immunol Res       Date:  2017-10-03       Impact factor: 4.818

8.  PPARγ inhibition boosts efficacy of PD-L1 Checkpoint Blockade Immunotherapy against Murine Melanoma in a sexually dimorphic manner.

Authors:  Bogang Wu; Xiujie Sun; Bin Yuan; Fei Ge; Harshita B Gupta; Huai-Chin Chiang; Jingwei Li; Yanfen Hu; Tyler J Curiel; Rong Li
Journal:  Int J Biol Sci       Date:  2020-03-05       Impact factor: 6.580

9.  Biological Function of PD-L2 and Correlation With Overall Survival in Type II Endometrial Cancer.

Authors:  Oliviero Marinelli; Daniela Annibali; Maria Beatrice Morelli; Laura Zeppa; Sandra Tuyaerts; Cristina Aguzzi; Consuelo Amantini; Federica Maggi; Benedetta Ferretti; Giorgio Santoni; Frédéric Amant; Massimo Nabissi
Journal:  Front Oncol       Date:  2020-10-28       Impact factor: 6.244

Review 10.  What Do We Have to Know about PD-L1 Expression in Prostate Cancer? A Systematic Literature Review. Part 7: PD-L1 Expression in Liquid Biopsy.

Authors:  Andrea Palicelli; Martina Bonacini; Stefania Croci; Alessandra Bisagni; Eleonora Zanetti; Dario De Biase; Francesca Sanguedolce; Moira Ragazzi; Magda Zanelli; Alcides Chaux; Sofia Cañete-Portillo; Maria Paola Bonasoni; Stefano Ascani; Antonio De Leo; Jatin Gandhi; Alessandro Tafuni; Beatrice Melli
Journal:  J Pers Med       Date:  2021-12-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.